192 related articles for article (PubMed ID: 34552066)
21. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.
Boi M; Rinaldi A; Kwee I; Bonetti P; Todaro M; Tabbò F; Piva R; Rancoita PM; Matolcsy A; Timar B; Tousseyn T; Rodríguez-Pinilla SM; Piris MA; Beà S; Campo E; Bhagat G; Swerdlow SH; Rosenwald A; Ponzoni M; Young KH; Piccaluga PP; Dummer R; Pileri S; Zucca E; Inghirami G; Bertoni F
Blood; 2013 Oct; 122(15):2683-93. PubMed ID: 24004669
[TBL] [Abstract][Full Text] [Related]
22. A novel model of controlling PD-L1 expression in ALK
Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
[TBL] [Abstract][Full Text] [Related]
23. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic large cell lymphoma involving the breast: a clinicopathologic study of 6 cases and review of the literature.
Miranda RN; Lin L; Talwalkar SS; Manning JT; Medeiros LJ
Arch Pathol Lab Med; 2009 Sep; 133(9):1383-90. PubMed ID: 19722744
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
[TBL] [Abstract][Full Text] [Related]
26. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
[TBL] [Abstract][Full Text] [Related]
27. Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.
Bonzheim I; Irmler M; Klier-Richter M; Steinhilber J; Anastasov N; Schäfer S; Adam P; Beckers J; Raffeld M; Fend F; Quintanilla-Martinez L
PLoS One; 2013; 8(5):e64544. PubMed ID: 23741337
[TBL] [Abstract][Full Text] [Related]
28. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
29. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
Horie R; Watanabe M; Ishida T; Koiwa T; Aizawa S; Itoh K; Higashihara M; Kadin ME; Watanabe T
Cancer Cell; 2004 Apr; 5(4):353-64. PubMed ID: 15093542
[TBL] [Abstract][Full Text] [Related]
30. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
32. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling.
Buchan SL; Al-Shamkhani A
PLoS One; 2012; 7(9):e45244. PubMed ID: 23028875
[TBL] [Abstract][Full Text] [Related]
33. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
34. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
35. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
37. The role of AP-1 and epigenetics in ALCL.
Schiefer AI; Vesely P; Hassler MR; Egger G; Kenner L
Front Biosci (Schol Ed); 2015 Jun; 7(2):226-35. PubMed ID: 25961698
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
[TBL] [Abstract][Full Text] [Related]
39. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
[TBL] [Abstract][Full Text] [Related]
40. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
